NECVAX NEO1
Alternative Names: NECVAX-NEO1Latest Information Update: 09 Aug 2024
At a glance
- Originator NEC Corporation; VAXIMM
- Developer NEC OncoImmunity
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours